Table 4.
Difference of the antimicrobial susceptibility between HV-positive and- negative of K. pneumoniae
| No. (%) of patients susceptible | |||
|---|---|---|---|
| Antimicrobial agent | HV-Positive isolates | HV-Negative isolates | P value |
| n = 14 | n = 29 | ||
| piperacillin | 8 (57.1) | 9 (31.0) | 0.101 |
| Cefazolin | 5 (35.7) | 10 (34.4) | 1.000 |
| Cefoxitin | 10 (71.4) | 14 (48.3) | 0.152 |
| Cefuroxime | 11 (78.6) | 11(37.9) | 0.012* |
| Ceftriaxone | 12 (85.7) | 12 (41.4) | 0.006* |
| Ceftazidime | 12 (85.7) | 12 (41.4) | 0.006* |
| Cefotaxime | 12 (85.7) | 13 (44.8) | 0.011* |
| Cefepime | 13 (92.9) | 23 (79.3) | 0.492 |
| Imipenem | 14 (100) | 28 (96.6) | 1.000 |
| Meropenem | 14 (100) | 28 (96.6) | 1.000 |
| Ciprofloxacin | 12 (85.7) | 15 (51.7) | 0.031* |
| Levofloxacin | 12 (85.7) | 16 (55.2) | 0.104 |
| Gentamicin | 14 (100) | 17(58.6) | 0.013* |
| Amikacin | 14 (100) | 18 (62.1) | 0.022* |
| Trimethoprim-sulfamethoxazole | 12 (85.7) | 17 (58.6) | 0.013* |
| ESBLs | 2 (14.3) | 18 (62.1) | 0.003* |
Values given as No. (%) of patients
ESBL, extended-spectrum β-lactamase
* P < 0.05 was considered to be statistically significant